Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.…
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Bicycle Therapeutics (NASDAQ: BCYC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 288 employees.
The shares were at 2.900 USD on 20 November 2026, down 55.8% over 52 weeks. Its 52-week range is 2.850 USD to 7.830 USD: the price is 63.0% below the high and 1.8% above the low.
Its market capitalisation is 203.27M USD.
Bicycle Therapeutics reports return on equity of -35.9%, an operating margin of -184.4% and revenue up 190.2% year over year.
It holds more cash than debt, a net cash position of 455.74M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 9.167 USD is 216.1% above the current price. The next earnings report is expected on 16 March 2027.